Emyria Data Validated, Care Model Reduces Opioids
Filed with ASX · · 31 pages · English
● Analysis of large drug community dispensing data shows a significant reduction in opioid use following commencement of a personalised treatment program involving cannabinoid medicine at Emyria’s Emerald Clinics ● Opioid prescription dispensing data provided by IQVIA (NYSE: IQV) and NostraData validates the quality and utility of Emyria’s proprietary clinical data ● The data show that, on average
Earlier from Emyria
- Emyria Obtains TGA Approval for Medical Grade Monitoring App
- Emyria and MMA launch MDMA-assisted therapy program for PTSD
- $5m Placement for Drug Registration and Treatment Pipeline
- Emyria and Cann Partner to Register CBD Product
- Emyria Adds Second Clinical Site in Perth
Later from Emyria
- Emyria Advances EMD-004 Program Towards Registration
- Emyria to Develop Novel Psychedelics Pipeline with UWA
- Emyria Executes Pure CBD Agreement with AltaSciences
- Emyria Appoints Expert Neuropharmacologist for MDMA Program
- Emyria Engages Calvert Labs for Preclinical CBD studies
Follow Emyria into a list and get an email when it puts out news.
Follow Emyria